Oluyemi Okupe Sells 101,993 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock in a transaction on Monday, November 25th. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66. Following the completion of the transaction, the chief financial officer now owns 109,392 shares in the company, valued at approximately $3,240,191.04. This represents a 48.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.79, for a total value of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Trading Down 1.1 %

NYSE:HIMS opened at $30.35 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06. The company’s 50-day moving average is $21.14 and its two-hundred day moving average is $19.57.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the business posted ($0.04) earnings per share. The company’s revenue was up 77.1% on a year-over-year basis. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Needham & Company LLC started coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $20.71.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its position in shares of Hims & Hers Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after purchasing an additional 136,907 shares during the period. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. State Street Corp grew its holdings in Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the period. Geode Capital Management LLC increased its stake in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares during the last quarter. Finally, Wellington Management Group LLP increased its stake in shares of Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.